Literature DB >> 11064959

Medication management of stimulants in pediatric practice settings: a national perspective.

K Hoagwood1, P S Jensen, M Feil, B Vitiello, V S Bhatara.   

Abstract

Using a nationally representative sample of office-based physicians, the management practices of pediatricians, psychiatrists, and family practice physicians were investigated. The major aims were to determine (1) what types of services these physicians were providing to children who received stimulants, (2) what factors predicted receipt of stimulants, and (3) whether these practices were concordant or discordant with professional consensus on diagnosis and treatment of attention-deficit hyperactivity disorders (ADHD). Prescribing and management practice data from the 1995 National Ambulatory Medical Care Survey (NAMCS) were analyzed for children ages 0 to 17 years who were seen for psychiatric problems and received stimulant medication. Results indicated that 2 million visits by children were made in 1995 to psychiatrists, pediatricians, or family practitioners in which psychotropic medications were prescribed. In pediatric visits where stimulant medication was prescribed, mental health counseling was provided 47.3% of the time and psychotherapy 21.6%. Follow-up arrangements were made in 79.1% of the visits. Psychiatrists were significantly more likely to provide psychotherapy and to specify follow-up visits than were pediatricians, but less likely to provide other health counseling. Controlling for demographic and physician effects, the factors with the most significant effect on the probability of receiving stimulants were geographic region (living in the South), race (being white), receiving mental health counseling, not receiving psychotherapy, and having health insurance. Less than 50% of pediatric visits for psychiatric reasons involving stimulant medications included any form of psychosocial intervention. In 21% of these visits, no recommendations were made for follow-up care. These practices diverge from National Institutes of Health (NIH) consensus panel recommendations and association-issued practice parameters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064959     DOI: 10.1097/00004703-200010000-00002

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  21 in total

1.  Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents.

Authors:  Laurel K Leslie; Jill Weckerly; John Landsverk; Richard L Hough; Michael S Hurlburt; Patricia A Wood
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

2.  Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison.

Authors:  Purva H Rawal; John S Lyons; James C MacIntyre; John C Hunter
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

3.  State infant/toddler program policies for eligibility and services provision for young children with autism.

Authors:  Aubyn C Stahmer; David S Mandell
Journal:  Adm Policy Ment Health       Date:  2007-01

4.  Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care medicaid program.

Authors:  Bonnie T Zima; Regina Bussing; Lingqi Tang; Lily Zhang; Susan Ettner; Thomas R Belin; Kenneth B Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-29       Impact factor: 8.829

5.  Geographic variation and disparity in stimulant treatment of adults and children in the United States in 2008.

Authors:  Douglas C McDonald; Sarah Kuck Jalbert
Journal:  Psychiatr Serv       Date:  2013-11-01       Impact factor: 3.084

6.  Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Authors:  Rebecca E Rosenberg; David S Mandell; Janet E Farmer; J Kiely Law; Alison R Marvin; Paul A Law
Journal:  J Autism Dev Disord       Date:  2010-03

7.  National quality measures for child mental health care: background, progress, and next steps.

Authors:  Bonnie T Zima; J Michael Murphy; Sarah Hudson Scholle; Kimberly Eaton Hoagwood; Ramesh C Sachdeva; Rita Mangione-Smith; Donna Woods; Hayley S Kamin; Michael Jellinek
Journal:  Pediatrics       Date:  2013-03       Impact factor: 7.124

8.  Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study.

Authors:  I-Chia Chien; Ching-Heng Lin; Yiing-Jenq Chou; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-04-04       Impact factor: 4.328

9.  Sociodemographic and economic comparisons of children prescribed longer-acting versus short-acting stimulant medications for attention deficit hyperactivity disorder.

Authors:  Jack Stevens; Jeffrey S Harman; Kelly J Kelleher
Journal:  J Behav Health Serv Res       Date:  2005 Oct-Dec       Impact factor: 1.505

10.  American parents' willingness to prescribe psychoactive drugs to children: a test of cultural mediators.

Authors:  David Cohen; Frank R Dillon; Hugh Gladwin; Mario De La Rosa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-29       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.